Pharmalot... Pharmalittle... Good Morning

Top of the morning to you. And a fine one it is, as the sun is shining brightly over the Pharmalot corporate campus and the short people are hustling of to their school houses at the appointed hour. This means we are free to dive into our workload without further delay. Of course, the same goes for you, yes? After all, there is much to be done. By the way, we are hosting a webinar next week on Off-Label Marketing issues and invite you to join us (

look here). We would also like to remind you that Pharmalot will be closed tomorrow for religious observance, but returns on Thursday. Meanwhile, here are some tidbits. Have a grand day...

J&J Hid Risk Risperdal Causes Male Breasts: Lawyer (Bloomberg News)

Quintiles Is Considering An IPO (Bloomberg News)

European Pharma Complains Over Pharmacovigilance Fees (Outsourcing Pharma)

Novo Nordisk Opens New R&D Center In China (Wall Street Journal)

Cosmo Pharma Hopes Dye Will Lure A Buyer (Bloomberg News)

Mallinckrodt Is Buying CNS Therapeutics For $100M (Minneapolis Star Tribune)

Royalty Pharma Seeks Lower Rate On Loans (Bloomberg News)

Cell Therapeutics Says Lymphoma Drug Shows Progress (MarketWatch)

Roche Backs Tiny Biotech With Genentech History (Xconomy)

Bayer Opens Finance Office In Poland (Property International)

EDITOR'S NOTE: Please check this post for updates

1 Comment

Sep 25, 2012 - 6:53pm
On J And J giving out popcorn and legos, and trying to hide the evidence of breasts growing on boys, it's just a shame that their new exec. isn't being forced to face the music in court. It would be the right thing - especially as he was in charge of the Risperdal roll-out.

For all we know, he could have discussed what other sorts of inducements the company was thinking of at the time, to get that coveted pediatric market....Barbie dolls, tinker toys, happy meals?